Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 11 studies | 26% ± 7% | |
endothelial cell | 11 studies | 25% ± 11% | |
basal cell | 8 studies | 30% ± 12% | |
epithelial cell | 7 studies | 39% ± 16% | |
astrocyte | 5 studies | 26% ± 5% | |
Mueller cell | 5 studies | 30% ± 14% | |
classical monocyte | 4 studies | 25% ± 6% | |
conventional dendritic cell | 4 studies | 35% ± 14% | |
capillary endothelial cell | 4 studies | 23% ± 2% | |
natural killer cell | 4 studies | 18% ± 2% | |
type II pneumocyte | 4 studies | 23% ± 8% | |
glutamatergic neuron | 4 studies | 34% ± 15% | |
enteroendocrine cell | 4 studies | 26% ± 11% | |
keratinocyte | 4 studies | 37% ± 14% | |
oligodendrocyte | 4 studies | 18% ± 2% | |
squamous epithelial cell | 3 studies | 41% ± 15% | |
hematopoietic precursor cell | 3 studies | 21% ± 2% | |
cardiac muscle cell | 3 studies | 19% ± 1% | |
ciliated cell | 3 studies | 29% ± 7% | |
macrophage | 3 studies | 18% ± 2% | |
GABAergic neuron | 3 studies | 30% ± 10% | |
dendritic cell | 3 studies | 36% ± 13% | |
transit amplifying cell | 3 studies | 28% ± 16% | |
goblet cell | 3 studies | 20% ± 3% | |
neuron | 3 studies | 30% ± 11% | |
abnormal cell | 3 studies | 17% ± 0% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 2072.08 | 458 / 459 | 100% | 36.47 | 1115 / 1118 |
thymus | 99% | 2248.77 | 647 / 653 | 100% | 37.44 | 604 / 605 |
brain | 99% | 2741.20 | 2620 / 2642 | 100% | 38.97 | 703 / 705 |
prostate | 98% | 2360.52 | 241 / 245 | 100% | 51.81 | 500 / 502 |
lung | 97% | 2324.81 | 562 / 578 | 100% | 39.69 | 1152 / 1155 |
esophagus | 96% | 3596.90 | 1390 / 1445 | 99% | 39.71 | 182 / 183 |
stomach | 95% | 1519.25 | 341 / 359 | 99% | 24.84 | 284 / 286 |
bladder | 95% | 1070.14 | 20 / 21 | 99% | 39.09 | 498 / 504 |
ovary | 92% | 1187.98 | 165 / 180 | 100% | 32.93 | 429 / 430 |
intestine | 91% | 1006.55 | 878 / 966 | 99% | 29.84 | 521 / 527 |
uterus | 89% | 1059.58 | 152 / 170 | 100% | 54.63 | 458 / 459 |
skin | 89% | 17581.83 | 1617 / 1809 | 99% | 39.70 | 468 / 472 |
pancreas | 88% | 1186.38 | 290 / 328 | 100% | 31.80 | 178 / 178 |
kidney | 98% | 1453.13 | 87 / 89 | 89% | 13.40 | 798 / 901 |
adrenal gland | 81% | 840.19 | 208 / 258 | 92% | 16.36 | 211 / 230 |
liver | 46% | 428.13 | 104 / 226 | 89% | 13.00 | 361 / 406 |
tonsil | 0% | 0 | 0 / 0 | 100% | 68.30 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 31.07 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 26.19 | 79 / 80 |
adipose | 98% | 1839.46 | 1181 / 1204 | 0% | 0 | 0 / 0 |
heart | 96% | 2034.62 | 824 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 93% | 11.69 | 27 / 29 |
blood vessel | 82% | 844.41 | 1090 / 1335 | 0% | 0 | 0 / 0 |
spleen | 59% | 522.68 | 141 / 241 | 0% | 0 | 0 / 0 |
muscle | 50% | 519.39 | 398 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 35% | 323.99 | 327 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001658 | Biological process | branching involved in ureteric bud morphogenesis |
GO_0002528 | Biological process | regulation of vascular permeability involved in acute inflammatory response |
GO_0072201 | Biological process | negative regulation of mesenchymal cell proliferation |
GO_0031333 | Biological process | negative regulation of protein-containing complex assembly |
GO_0045657 | Biological process | positive regulation of monocyte differentiation |
GO_0045669 | Biological process | positive regulation of osteoblast differentiation |
GO_0043433 | Biological process | negative regulation of DNA-binding transcription factor activity |
GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
GO_0030178 | Biological process | negative regulation of Wnt signaling pathway |
GO_0048662 | Biological process | negative regulation of smooth muscle cell proliferation |
GO_0009952 | Biological process | anterior/posterior pattern specification |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0032091 | Biological process | negative regulation of protein binding |
GO_0060633 | Biological process | negative regulation of transcription initiation by RNA polymerase II |
GO_0005634 | Cellular component | nucleus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0030877 | Cellular component | beta-catenin destruction complex |
GO_1990711 | Cellular component | beta-catenin-ICAT complex |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0008013 | Molecular function | beta-catenin binding |
GO_0005515 | Molecular function | protein binding |
GO_0070016 | Molecular function | armadillo repeat domain binding |
Gene name | CTNNBIP1 |
Protein name | Beta-catenin-interacting protein 1 (Inhibitor of beta-catenin and Tcf-4) |
Synonyms | ICAT |
Description | FUNCTION: Prevents the interaction between CTNNB1 and TCF family members, and acts as a negative regulator of the Wnt signaling pathway. . |
Accessions | Q9NSA3 ENST00000400904.7 ENST00000377258.5 ENST00000377263.6 ENST00000377256.1 |